Sucralfate versus placebo in reflux esophagitis. A double-blind multicenter study. 1988

L Carling, and J Cronstedt, and A Engqvist, and I Kagevi, and B Nyström, and L E Svedberg, and E Thorhallsson, and P Unge, and P E Wingren
Dept. of Medicine, Bollnäs Hospital Sweden.

The healing capacity and symptom relief were studied in 138 patients with symptomatic endoscopically verified reflux esophagitis treated with sucralfate (n = 69) or placebo (n = 69), 1 g four times daily (granules suspended in half a glass of water), for at most up to 12 weeks. The reflux esophagitis (modified Savary-Miller scale) was distributed with 71 patients having grade 1, 39 patients having grade 2 or 3, and 28 patients having grade 4. All patients were told to follow the antireflux regimen. Antacid tablets were supplied, to be used only for the relief of severe pain, and were counted. The esophageal lesions were completely healed in 42% (sucralfate) and 35% (placebo) after 6 weeks of treatment (NS). Corresponding cumulative healing rates at 12 weeks of treatment were 54% and 41% (NS), respectively. The symptom improvement, however, was significantly better in the sucralfate group after 3 weeks of treatment. The results indicate a symptomatic benefit of sucralfate in reflux esophagitis.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004942 Esophagitis, Peptic INFLAMMATION of the ESOPHAGUS that is caused by the reflux of GASTRIC JUICE with contents of the STOMACH and DUODENUM. Esophagitis, Reflux,Esophagitides, Peptic,Esophagitides, Reflux,Peptic Esophagitides,Peptic Esophagitis,Reflux Esophagitides,Reflux Esophagitis
D004945 Esophagoscopy Endoscopic examination, therapy or surgery of the esophagus. Esophagoscopic Surgical Procedures,Surgical Procedures, Esophagoscopic,Esophagoscopic Surgery,Surgery, Esophagoscopic,Esophagoscopic Surgeries,Esophagoscopic Surgical Procedure,Esophagoscopies,Procedure, Esophagoscopic Surgical,Procedures, Esophagoscopic Surgical,Surgeries, Esophagoscopic,Surgical Procedure, Esophagoscopic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013392 Sucralfate A basic aluminum complex of sulfated sucrose. Aluminum Sucrose Sulfate,Antepsin,Basic Aluminum Sucrose Sulfate,Carafate,Ulcerban,Ulcogant,Ulsanic,Sulfate, Aluminum Sucrose

Related Publications

L Carling, and J Cronstedt, and A Engqvist, and I Kagevi, and B Nyström, and L E Svedberg, and E Thorhallsson, and P Unge, and P E Wingren
August 1991, The American journal of medicine,
L Carling, and J Cronstedt, and A Engqvist, and I Kagevi, and B Nyström, and L E Svedberg, and E Thorhallsson, and P Unge, and P E Wingren
August 1987, Journal of clinical gastroenterology,
L Carling, and J Cronstedt, and A Engqvist, and I Kagevi, and B Nyström, and L E Svedberg, and E Thorhallsson, and P Unge, and P E Wingren
December 1988, Journal of clinical gastroenterology,
L Carling, and J Cronstedt, and A Engqvist, and I Kagevi, and B Nyström, and L E Svedberg, and E Thorhallsson, and P Unge, and P E Wingren
February 1991, Scandinavian journal of gastroenterology,
L Carling, and J Cronstedt, and A Engqvist, and I Kagevi, and B Nyström, and L E Svedberg, and E Thorhallsson, and P Unge, and P E Wingren
September 1990, International journal of clinical pharmacology, therapy, and toxicology,
L Carling, and J Cronstedt, and A Engqvist, and I Kagevi, and B Nyström, and L E Svedberg, and E Thorhallsson, and P Unge, and P E Wingren
December 1991, The American journal of gastroenterology,
L Carling, and J Cronstedt, and A Engqvist, and I Kagevi, and B Nyström, and L E Svedberg, and E Thorhallsson, and P Unge, and P E Wingren
May 1983, Ugeskrift for laeger,
L Carling, and J Cronstedt, and A Engqvist, and I Kagevi, and B Nyström, and L E Svedberg, and E Thorhallsson, and P Unge, and P E Wingren
January 1981, Journal of clinical gastroenterology,
L Carling, and J Cronstedt, and A Engqvist, and I Kagevi, and B Nyström, and L E Svedberg, and E Thorhallsson, and P Unge, and P E Wingren
October 1979, Gastroenterology,
L Carling, and J Cronstedt, and A Engqvist, and I Kagevi, and B Nyström, and L E Svedberg, and E Thorhallsson, and P Unge, and P E Wingren
June 1992, Digestive diseases and sciences,
Copied contents to your clipboard!